Status:
COMPLETED
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
Lead Sponsor:
University of Mary Hardin-Baylor
Collaborating Sponsors:
Indus Biotech Ltd. Pvt.
Conditions:
Muscle Damage
Inflammation
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
This is a randomized, repeated measures and double blind study which measures the effect of fenugreek extract on markers of muscle damage and inflammation in non-resistance trained males. Participants...
Detailed Description
Subjects expressing interest in doing the study will be interviewed in the UMHB Human Performance Lab (HPL) to determine whether they qualify to participate in the study. Upon qualification, participa...
Eligibility Criteria
Inclusion
- Subjects will be males between the age of 18-45;
- Subjects will have not been participating in a structured resistance training program in the past 6 months;
- Subjects will be provided written and dated informed consent to participate in the study;
- Subjects will be willing and able to comply with the protocol;
- Subjects will be apparently healthy and free from disease, as determined by a health history questionnaire;
- Subjects will agree to abstain from exercise 48 hours prior to each testing visit;
- Subjects will agree to fast for 10 hours prior to each testing visit;
- Subjects will be agree to refrain from tobacco use, alcohol and/or caffeine consumption and/or smoking 12 hours prior to each testing visit;
- Subjects will agree to refrain from taking any supplement that may interfere with study supplementation for the remainder of the study.
Exclusion
- Subject has taken ergogenic levels of nutritional supplements that may affect muscle mass (e.g., creatine, HMB) or anabolic/catabolic hormone levels (e.g., androstenedione, DHEA, etc.) within 3 months prior to the start of the study;
- Subject is unable to complete blood draws needed at each testing session;
- Subject reports any unusual adverse events associated with this study that in consultation with the supervising physician recommends removal from the study;
- Subject does not complete 90% of resistance training program assigned;
- Subject is unable to complete overreaching protocol during overreaching week;
Key Trial Info
Start Date :
September 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03318731
Start Date
September 21 2017
End Date
August 30 2019
Last Update
September 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMHB Human Performance Lab
Belton, Texas, United States, 76513